Drug profile · INN
insulin aspart
FIASP PENFILL
insulin aspart (FIASP PENFILL) is a insulin receptor agonist. Associated with NovoThirteen. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — insulin aspart
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- SUBCUTANEOUS
- Patents
- 5
- Programs
- 19
- Data quality
- 0.84
Quick answer
insulin aspart (FIASP PENFILL) is a insulin receptor agonist. Associated with NovoThirteen. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
EP 4732903
COKRISTALLE VON PITOLISTANTHYDROCHLORID
granted -
US 12325732
Pro-insulin aspart structure and method for preparing insulin aspart
granted -
US 2020024256
TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
granted -
EP 3378477
NEUE THERAPEUTISCHE VERWENDUNGEN VON H3-LIGANDEN
granted -
EP 2014653
Neue Dicarbonsäurederivate als S1P1 Rezeptor Agonisten
granted
Frequently asked questions
What is insulin aspart?
insulin aspart (FIASP PENFILL) is a insulin receptor agonist. Associated with NovoThirteen. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for insulin aspart?
FIASP PENFILL is a marketed brand name for insulin aspart. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin aspart?
insulin aspart has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.